BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38564942)

  • 1. Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment.
    Han X; Wang W; Wang R; Zhang W; Zhu L; Xu Q; Guo W; Gu Y
    Biochem Biophys Res Commun; 2024 May; 709():149812. PubMed ID: 38564942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving regorafenib's organ target precision via nano-assembly to change its delivery mode abolishes chemoresistance and liver metastasis of colorectal cancer.
    Liu J; Fu D; Wang K; Yuan Y; Deng Y; Shi L; Li M; Zhou C; Lu X; Lv Q; Wang G; Wang L; Wang Z
    J Colloid Interface Sci; 2022 Feb; 607(Pt 1):229-241. PubMed ID: 34500422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular insight of regorafenib treatment for colorectal cancer.
    Arai H; Battaglin F; Wang J; Lo JH; Soni S; Zhang W; Lenz HJ
    Cancer Treat Rev; 2019 Dec; 81():101912. PubMed ID: 31715423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
    Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
    Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib in the treatment of metastatic colorectal cancer.
    de la Fouchardière C
    Future Oncol; 2018 Sep; 14(22):2239-2246. PubMed ID: 29569472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SHP-1 is a target of regorafenib in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Lin H; Hung MH; Chen YL; Huang JW; Tai WT; Yu HC; Chen KF
    Oncotarget; 2014 Aug; 5(15):6243-51. PubMed ID: 25071018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report.
    Yoshino K; Manaka D; Kudo R; Kanai S; Mitsuoka E; Kanto S; Hamasu S; Konishi S; Nishitai R
    J Med Case Rep; 2017 Aug; 11(1):227. PubMed ID: 28818109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
    Chen D; Wei L; Yu J; Zhang L
    Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
    Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
    Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
    Daudigeos-Dubus E; Le Dret L; Lanvers-Kaminsky C; Bawa O; Opolon P; Vievard A; Villa I; Pagès M; Bosq J; Vassal G; Zopf D; Geoerger B
    PLoS One; 2015; 10(11):e0142612. PubMed ID: 26599335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the safety and efficacy of regorafenib in the treatment of solid cancers.
    Chan SL; Ma BB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1607-14. PubMed ID: 25316322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages.
    Ou DL; Chen CW; Hsu CL; Chung CH; Feng ZR; Lee BS; Cheng AL; Yang MH; Hsu C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway.
    Lin XL; Xu Q; Tang L; Sun L; Han T; Wang LW; Xiao XY
    PLoS One; 2017; 12(5):e0177335. PubMed ID: 28489887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.